NASH Race No More Clear After AASLD Than Before
Genfit joins Intercept in Phase III, but Tobira thinks its Phase IIb study will position it well for registrational studies. Intercept expects to get to market first in primary biliary cholangitis, which could be a significant market opportunity.
You may also be interested in...
Sponsors in the hotly pursued and yet untapped field of non-alcoholic steatohepatitis think that selection of different primary or co-primary endpoints could help differentiate their programs in the competitive space.
New research links the use of stents and balloons coated with the drug paclitaxel to an increased risk of lower-leg amputation shortly following surgery. The study was conducted by Greek researcher Konstantinos Katsanos, who previously found an increased mortality risk in paclitaxel-treated patients.
Monia told Scrip at the J.P. Morgan Healthcare Conference that the company will be more selective about partnerships going forward and build commercial capabilities to market Ionis-owned drugs.